Several members of this receptor family (HER2, EGFR, VEGFR, etc.)have become important targets for clinical anti‐cancer therapies (Regad, 2015; Seshacharyulu et al., 2012; Tai et al., 2010), including small molecular inhibitors and antibody‐based therapies. This evidence concerns the gene ERBB2 and cancer.